Metcela

About:

Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.

Website: https://www.metcela.com/en/

Twitter/X: metcelainc

Top Investors: F-Prime Capital, Sony, Beyond Next Ventures, UTEC - The University of Tokyo Edge Capital Partners, Eight Roads Ventures

Description:

Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure. It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan.